Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DYN vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPT Captures Overall Composite Edge (52.4 HOLD vs 47.5 HOLD), While DYN Leads 5–0 on Growth & Valuation Pillars

RAPT Overall Winner 6-Pillar Tally: DYN 5 – 0 RAPT (1 Tie) Matrix Metrics: DYN 3 – 3 RAPT

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Dyne Therapeutics, Inc. (DYN) on higher Unified Composite conviction (52.4/100 HOLD vs. 47.5/100 HOLD) after splitting the core matrix 3–3 (led by composite factor balance), while DYN wins 5–0 across the 6-pillar growth and valuation breakdown. DYN trades at $16.70 (N/M Forward P/E, 0.0% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. DYN 47.5/100 HOLD) and -0.02β · 2% Vol risk profile, whereas DYN leads top-line expansion (+0.0% YoY revenue growth, 0.19x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DYN vs RAPT
DYN NASDAQ
Dyne Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$16.70
-2.71% 1D
Market Cap $3.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.72β · 58% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 33.0 Fund 53.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -17.2%) with fading momentum, RSI 46
RSI-14: 45.9 · SMA20: $17.09 · SMA50: $16.81
RAPT NASDAQ Head-to-Head Winner
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (DYN 5 – 0 RAPT)

Columns: Metric · DYN · RAPT
1. Valuation Multiples DYN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.19x N/M
EV / Revenue N/M N/M
2. Growth & Scale DYN
Revenue Growth (YoY) +0.0% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $3.2B $1.7B
3. Profitability & Quality DYN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -74.6% -85.4%
4. Balance Sheet & Cash Flow DYN
Cash Generation (TTM) -$569M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $694M Net Cash $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DYN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 124.9% (25th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 0.10x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DYN (3) vs RAPT (3)
Institutional Metric DYN RAPT Criterion Row Edge
Market Capitalization
Scale
$3.2B $1.7B Larger Scale DYN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -100.0% Higher Growth DYN
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-74.6% -85.4% Higher ROE DYN
52-Week Range Position
Momentum
20% ($14–$27) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
1.72β · 58% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.19x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$569M ($694M Net Cash) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +10.36 pp
DYN: -9.68% · RAPT: +0.68%
3M Horizon RAPT +98.15 pp
DYN: -23.71% · RAPT: +74.44%
6M Horizon RAPT +116.0 pp
DYN: -14.05% · RAPT: +101.95%
1Y Horizon RAPT +116.0 pp
DYN: -14.05% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DYN vs RAPT. Trailing 12-month operating profitability (DYN 0.0% vs RAPT 0.0%) and valuation multiples (DYN N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DYN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.6% · N/M
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DYN BREAKDOWN
68d in phase · OBV ACCUMULATION
Current IV 124.9%
IV Percentile 25th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DYN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DYN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DYN vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Dyne Therapeutics, Inc. (DYN) on higher Unified Composite conviction (52.4/100 HOLD vs. 47.5/100 HOLD) after splitting the core matrix 3–3 (led by composite factor balance), while DYN wins 5–0 across the 6-pillar growth and valuation breakdown. DYN trades at $16.70 (N/M Forward P/E, 0.0% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. DYN 47.5/100 HOLD) and -0.02β · 2% Vol risk profile, whereas DYN leads top-line expansion (+0.0% YoY revenue growth, 0.19x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DYN is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 45.9); meanwhile RAPT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 79.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DYN leads the Growth & Scale pillar: DYN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DYN generates N/A in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, DYN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

DYN screens cheaper on headline valuation multiples. DYN trades at N/M Forward P/E, N/M Trailing P/E, 0.19x PEG, and N/M EV/Revenue (unreported FCF margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DYN (-74.6% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, DYN carries 124.9% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.72β · 58% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.